Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

The company's latest presentation supports the idea that its lead program will make billions.

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...